Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights
Tectonic Therapeutic, Inc. (TECX)
Company Research
Source: GlobeNewswire
Positive topline data from Part B of the TX45 Phase 1b trial demonstrated improvements in both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH-HFrEF”)Expect to initiate TX2100 Phase 1 clinical trial in healthy volunteers in Q1’2026 as a potential treatment for Hereditary Hemorrhagic Telangiectasia (“HHT”)TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45’s safety and hemodynamic effects in patients with Pulmonary Hypertension associated with Interstitial Lung Disease (“PH-ILD”, Group 3 PH) to expand the therapeutic breadth of TX45Ongoing TX45 APEX Phase 2 clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”) continues to enroll; topline results expected in 2026Cash and cash equivalents were $268.4 million as of September 30, 2025, expected to provide cash runway into Q4’2028 WATERTOW
Show less
Read more
Impact Snapshot
Event Time:
TECX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TECX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TECX alerts
High impacting Tectonic Therapeutic, Inc. news events
Weekly update
A roundup of the hottest topics
TECX
News
- Tectonic Therapeutic to Participate in December Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Tectonic Therapeutic to Participate in December Investor ConferencesGlobeNewswire
- Tectonic: Strong Buy On Positive Phase 1b TX45 Data And 2026 Inflection Point [Seeking Alpha]Seeking Alpha
- Tectonic Therapeutic GAAP EPS of -$1.02 beats by $0.05 [Seeking Alpha]Seeking Alpha
- Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEFGlobeNewswire
TECX
Earnings
- 11/6/25 - Beat
TECX
Analyst Actions
- 10/20/25 - Wells Fargo & Company
TECX
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/6/25 - Form 10-Q
- TECX's page on the SEC website